Mohammad Soroura, Maged El Shorbagy, M. Shawky, T. Borg, K. Wahba, A. Reyad
{"title":"循环母体血清细胞游离胎儿DNA水平预测子痫前期","authors":"Mohammad Soroura, Maged El Shorbagy, M. Shawky, T. Borg, K. Wahba, A. Reyad","doi":"10.21608/ebwhj.2020.28158.1093","DOIUrl":null,"url":null,"abstract":"Background: Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of 5–15%. It is one of the main causes of maternal and perinatal morbidity and mortality globally and accounts for 50 000–60 000 deaths annually, with a predominance in the low- and middle-income countriesThere is a great need to have a test for predicition of women at high risk of developing preeclampsia. Aim of the Work: to assess the accuracy of maternal serum Cff-DNA concentration levels in primigravidas 10-20 weeks gestation as a predictive test for the development of preeclampsia. Patients and Methods: A nested case-control study was conducted on 26 patients with PE and 26 matched controls rimigravidas in 10-20 weeks gestation recruited from Ain-Shams University Maternity Hospital. Laboratory work was done in Ali Khalifa laboratory of the biochemistry department, Faculty of Medicine, Ain-Shams University. Results: The study showed a statistically significant increase median of severe preeclampsia compared to non severepreeclampsia and control group according to cff-DNA (GE/ml). Also the study results revealed a statistically significant increase median of preeclampsia group compared to control group according to BMI, GA (wks), SBP and DBP. Conclusion: Cff-DNA quantification can be considered as a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Circulating Maternal Serum Cell Free Fetal DNA Levels for prediction of Preeclampsia\",\"authors\":\"Mohammad Soroura, Maged El Shorbagy, M. Shawky, T. Borg, K. Wahba, A. Reyad\",\"doi\":\"10.21608/ebwhj.2020.28158.1093\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of 5–15%. It is one of the main causes of maternal and perinatal morbidity and mortality globally and accounts for 50 000–60 000 deaths annually, with a predominance in the low- and middle-income countriesThere is a great need to have a test for predicition of women at high risk of developing preeclampsia. Aim of the Work: to assess the accuracy of maternal serum Cff-DNA concentration levels in primigravidas 10-20 weeks gestation as a predictive test for the development of preeclampsia. Patients and Methods: A nested case-control study was conducted on 26 patients with PE and 26 matched controls rimigravidas in 10-20 weeks gestation recruited from Ain-Shams University Maternity Hospital. Laboratory work was done in Ali Khalifa laboratory of the biochemistry department, Faculty of Medicine, Ain-Shams University. Results: The study showed a statistically significant increase median of severe preeclampsia compared to non severepreeclampsia and control group according to cff-DNA (GE/ml). Also the study results revealed a statistically significant increase median of preeclampsia group compared to control group according to BMI, GA (wks), SBP and DBP. Conclusion: Cff-DNA quantification can be considered as a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia.\",\"PeriodicalId\":224226,\"journal\":{\"name\":\"Evidence Based Womenʼs Health Journal\",\"volume\":\"19 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-12-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Evidence Based Womenʼs Health Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21608/ebwhj.2020.28158.1093\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Womenʼs Health Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/ebwhj.2020.28158.1093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Circulating Maternal Serum Cell Free Fetal DNA Levels for prediction of Preeclampsia
Background: Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of 5–15%. It is one of the main causes of maternal and perinatal morbidity and mortality globally and accounts for 50 000–60 000 deaths annually, with a predominance in the low- and middle-income countriesThere is a great need to have a test for predicition of women at high risk of developing preeclampsia. Aim of the Work: to assess the accuracy of maternal serum Cff-DNA concentration levels in primigravidas 10-20 weeks gestation as a predictive test for the development of preeclampsia. Patients and Methods: A nested case-control study was conducted on 26 patients with PE and 26 matched controls rimigravidas in 10-20 weeks gestation recruited from Ain-Shams University Maternity Hospital. Laboratory work was done in Ali Khalifa laboratory of the biochemistry department, Faculty of Medicine, Ain-Shams University. Results: The study showed a statistically significant increase median of severe preeclampsia compared to non severepreeclampsia and control group according to cff-DNA (GE/ml). Also the study results revealed a statistically significant increase median of preeclampsia group compared to control group according to BMI, GA (wks), SBP and DBP. Conclusion: Cff-DNA quantification can be considered as a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia.